<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David B Clifford, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H547026890"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Changes in memory, concentration, attention, and motor skills are common in patients with HIV and present a diagnostic challenge to the clinician [<a href="#rid1">1</a>]. Since these symptoms can be caused by a variety of disorders, accurate diagnosis is critical for patient treatment [<a href="#rid2">2</a>]. When not clearly attributable to an alternate cause other than HIV infection, such impairments have been collectively classified as HIV-associated neurocognitive disorders (HAND).</p><p>The epidemiology, clinical manifestations, and diagnosis of HIV-associated neurocognitive disorders will be discussed here. Management of HIV-associated neurocognitive disorders are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/98405.html" rel="external">"HIV-associated neurocognitive disorders: Management"</a>.)</p><p>An overview of the range of neuropsychiatric conditions associated with HIV infection and more detailed reviews of other specific conditions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4860.html" rel="external">"Overview of the neuropsychiatric aspects of HIV infection and AIDS"</a> and  <a class="medical medical_review" href="/z/d/html/4864.html" rel="external">"Depression, mania, and schizophrenia in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3725.html" rel="external">"Substance use disorder in patients with HIV"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The presence of neurocognitive deficits in certain individuals with HIV, without alternative explanation other than HIV infection, has long been recognized. However, the terminology to refer to this phenomenon has undergone substantial evolution since its initial characterization. In order to assist in diagnosis and categorization for research and clinical purposes, a working group supported by the United States National Institutes of Health published a classification scheme in 2007 that was initially proposed by the HIV Neurobehavioral Research Center at the University of California, San Diego [<a href="#rid3">3</a>]. This classification, often referred to as the "Frascati criteria," has been widely, but not universally, adopted [<a href="#rid4">4,5</a>]. It includes three levels of impaired neuropsychological test performance and functional impairment within an umbrella term, HIV-associated neurocognitive disorders (HAND):</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic neurocognitive impairment (ANI) – defined by a score of one standard deviation or more below the mean in at least two cognitive domains on standardized neuropsychological testing without a symptomatic or observable functional impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild neurocognitive disorder (MND) – defined by a score of one standard deviation or more below the mean in at least two cognitive domains on standardized neuropsychological testing with at least mild symptomatic or functional impairment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV-associated dementia (HAD) – defined by a score of two standard deviations or more below the mean in at least two cognitive domains on standardized neuropsychological testing with concomitant impairment in activities of daily living.</p><p></p><p>The definitions are applied only when the observed impairment cannot be explained by other conditions, either alternative neurological diagnoses (such as opportunistic infection, stroke, or metabolic or toxic encephalopathy) or underlying "confounding" comorbidities that might alter neuropsychological test performance (such as severe substance abuse, prior head trauma, or severe psychiatric disease). </p><p>These diagnostic categories were developed to apply a common set of criteria for research studies and, in the strict sense, they should not be used in the clinical setting without formal neuropsychological testing. However, because of the functional impairment associated with HAD, it is usually possible to apply this term to the severe form. The two milder forms of HAND require this testing for characterization, and, in particular, ANI cannot be diagnosed without formal testing. </p><p>HAD has also been previously referred to as AIDS dementia complex, HIV encephalitis, or HIV encephalopathy, all terms that referred to a circumscribed, often subacute syndrome of progressive cognitive and motor dysfunction. (See <a class="local">'HIV-associated dementia'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>HIV disseminates to the central nervous system (CNS) during the initial days of systemic infection and can be detected in the cerebrospinal fluid (CSF) of most untreated patients thereafter [<a href="#rid6">6-11</a>]. However, the character of CSF infection changes over the course of infection and disease evolution. Initially, CSF viruses are genetically identical to those in blood and likely originate from trafficking CD4 cells. Later, CNS infection can become "compartmentalized," with the virus evolving independently from the virus found in blood. Additionally, the cell tropism of the CNS virus may change to become largely macrophage-tropic (M-tropic), in contrast to blood virus which characteristically maintains tropism for T-lymphocytes. </p><p>Whether viruses with M-tropism originate within the CNS or are introduced by infected monocytes is uncertain. However, macrophages and microglia are clearly critical to the switch from seemingly benign meningeal infection involving mainly T-lymphocytes to a more invasive encephalitis. Perivascular macrophages and related cells sustain compartmentalized brain infection and, whether infected or not, serve as important sources of the toxic signaling pathways involved in brain dysfunction that underlie HIV-associated dementia (HAD) and perhaps milder forms of HIV-neurocognitive disorders [<a href="#rid12">12</a>]. </p><p>While HIV also appears to infect astrocytes [<a href="#rid13">13-15</a>], this is usually nonproductive (ie, does not propagate infection), and its pathogenic significance remains uncertain. There is little evidence that HIV infects neurons or oligodendrocytes. Thus, alteration of the metabolism or death of such cells occurs by "indirect" mechanisms, through the aforementioned toxic signaling pathways, which likely involve both viral and cellular molecules [<a href="#rid16">16</a>]. </p><p>Autopsy studies of AIDS patients with HAD show characteristic white matter pallor, microglial nodules, multinucleated giant cells, and perivascular infiltrates [<a href="#rid17">17-19</a>]. Basal ganglia and nigrostriatal structures can be affected early in the course of the dementia, with subsequent diffuse neuronal loss resulting in up to 40 percent reduction in frontal and temporal neurons. More subtle structural brain changes (eg, decreased cortical grey matter volume) may be detected even within the first year of HIV infection in the absence of overt encephalitis more clearly associated with HAD [<a href="#rid20">20</a>]. However, there are no specific pathologic findings associated with milder forms of HAND (ie, minor neurocognitive disorder [MND] and asymptomatic neurocognitive impairment [ANI]). </p><p>Although antiretroviral therapy (ART) reduces HIV RNA in CSF, a substantial proportion of patients continue to show biomarker evidence of mild immune activation within the CNS even after years of durable viral suppression [<a href="#rid21">21</a>]. The pathophysiologic mechanisms that drive this persistent inflammatory response are unknown, although persistent CNS infection below levels detected in CSF is one possible explanation [<a href="#rid22">22-27</a>].</p><p>Other comorbidities that are common in patients with HIV may also play a pathogenic role in the development of neurocognitive impairment. (See <a class="local">'Comorbidities'</a> below.) </p><p class="headingAnchor" id="H26420625"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H49824933"><span class="h2">Prevalence in the ART era</span><span class="headingEndMark"> — </span>The widespread use of suppressive combination antiretroviral therapy (ART) has been associated with a marked decrease in the incidence of more severe neurocognitive deficits (ie, HIV-associated dementia [HAD]) [<a href="#rid28">28</a>]. Data from 15,380 patients with HIV followed in the CASCADE cohort (Concerted Action on Seroconversion to AIDS and Death in Europe) demonstrated a decrease in the incidence of HAD from 6.49 per 1000 person-years in the pre-ART era to 0.66 per 1000 person-years by 2003 to 2006 [<a href="#rid29">29</a>]. Similarly, a Danish population study reported that the incidence of severe neurological deficits in those with HIV infection was approaching that of the uninfected population [<a href="#rid30">30</a>].</p><p>In contrast to the major impact of ART on the incidence of HAD, a number of reports document a continued, substantial prevalence of milder impairment on testing in the setting of HIV infection (ranging from 20 to 69 percent in various series), even among patients with viral suppression [<a href="#rid31">31-38</a>]. In a study of 1521 patients with HIV from the eras before and after combination ART, neurocognitive impairment of any type was seen slightly more frequently in the post-ART compared with pre-ART cohorts (40 versus 33 percent, respectively) [<a href="#rid39">39</a>]. In a separate analysis of the same post-ART cohort, the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study, asymptomatic neurocognitive impairment (ANI) was most common, occurring in 33 percent, with mild neurocognitive disorder in 12 percent and HAD in only 2 percent of 1316 patients with HIV (the majority were on ART) [<a href="#rid35">35</a>].</p><p>The pattern of neuropsychological impairment seen in patients with HIV may also be affected by the use of ART. Whereas early reports of HAD emphasized the "subcortical" character of the dementia associated with HIV, with prominent slowing of processing and difficulty with attention and concentration, more recent observations have suggested a more "cortical" pattern of deficits [<a href="#rid40">40</a>].</p><p>A critical issue is whether milder cognitive impairment in virally suppressed patients is a residual effect of earlier, possibly subclinical brain injury that developed before treatment was started or whether brain injury can continue despite effective viral suppression. This issue is not yet fully resolved. Additionally, the frequency or degree to which the cognitive impairments in treated patients can be attributed to HIV infection itself is unclear [<a href="#rid41">41</a>] (see <a class="local">'Comorbidities'</a> below). Finally, there is concern that ART itself may have chronic toxic effects on the brain and contribute to the impairments in test performance [<a href="#rid42">42</a>]. A study that followed a subset of patients from the CHARTER cohort with repeated neuropsychological testing over a mean of three years noted a stable neurocognitive status in 61 percent, improvement in 17 percent, and worsening in 23 percent [<a href="#rid37">37</a>]. The factors associated with neurocognitive deterioration were complex and related to HIV disease and treatment status, but also involved other comorbid conditions.</p><p class="headingAnchor" id="H886399"><span class="h3">Compared with individuals without HIV</span><span class="headingEndMark"> — </span>Neurocognitive deficits are reported to be more common in individuals with HIV, including those using or not using ART, than in those without HIV in many [<a href="#rid39">39,43,44</a>], but not all [<a href="#rid31">31,45</a>], studies. One large study compared the prevalence of neurocognitive impairment as measured by comprehensive neuropsychological testing among several cohorts of patients with HIV (n = 1521) and patients without HIV (n = 273) from the eras before and after the introduction of combination ART (1988 to 1995 and 1999 to 2004, respectively) [<a href="#rid39">39</a>]. The prevalence of any impairment was 16 to 19 percent among patients without HIV, but ranged from 25 to 52 percent among individuals with HIV, depending on the era (pre- or post-ART) and disease state. By contrast, in a subsequent study of 200 patients with HIV, among whom the median CD4 cell count was 546 cells/microL and HIV viral suppression was achieved in 55 percent, the rate of cognitive impairment was comparable to that observed in 50 controls without HIV [<a href="#rid31">31</a>]. Similarly, in a study of over 1000 women, the effect of HIV status on cognition was less than that of years of education, age, race, income, and reading level [<a href="#rid46">46</a>]. </p><p class="headingAnchor" id="H7"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for the development of HIV-associated neurocognitive disorders (HAND) include HIV disease factors, other comorbidities, and possibly host genetic factors. </p><p class="headingAnchor" id="H261704439"><span class="h3">HIV disease factors</span><span class="headingEndMark"> — </span>In several studies, lower nadir CD4 cell count has been associated with an increased risk of neurocognitive impairment among patients with HIV on ART [<a href="#rid33">33,35,47</a>]. In the CASCADE cohort of 15,380 patients with HIV followed longitudinally, risk factors for the development of HAD specifically included lower CD4 cell counts, older age at seroconversion, duration of HIV infection, and the presence of a prior AIDS-defining diagnosis [<a href="#rid29">29</a>]. A period of severe immunosuppression appears to confer a long-lasting impact on neuropsychiatric performance regardless of subsequent viral suppression and immune reconstitution. </p><p>The underlying reasons for this are not known. There is possibly a higher incidence of HIV-associated brain injury in those with more advanced immunosuppression, which leaves residual impairment and a legacy of diminished "brain reserve" [<a href="#rid8">8</a>]. Alternatively, advanced infection and immune injury may initiate a neuropathic process that continues even after treatment and CD4 cell restoration, regardless of ongoing viral replication or gene expression within the CNS. Evolution of compartmentalized infection with macrophage tropism, which is more common in advanced infection, may predispose to persistent CNS infection [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H261704796"><span class="h3">Comorbidities</span><span class="headingEndMark"> — </span>Adults older than 50 years of age with HIV have an increased prevalence of neurocognitive deficits and dementia compared with patients younger than 40 years [<a href="#rid49">49-51</a>]. However, whether increased age affects cognitive function in patients with HIV to a greater extent than in patients without HIV is unclear. A 12-year longitudinal study of 402 patients with HIV found that comorbidities such as diabetes, hypertension, chronic pulmonary disease, frailty, neuropathic pain, depression, and lifetime history of cannabis use disorder contributed to declining cognitive status while the effects of aging and HIV status failed to predict decline [<a href="#rid41">41</a>]. In another study, age greater than 50 years was associated with similarly decreased performance on neuropsychological testing among 115 individuals with HIV and 30 without [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/3735.html" rel="external">"HIV infection in older adults"</a>.)</p><p>In an aging HIV population, Alzheimer disease, the most common age-associated degenerative brain disease, is increasingly reported. Emerging therapeutics specific to Alzheimer disease make it critical that this diagnosis be considered regardless of HIV status. Indeed, since HAND is most often relatively static, a subacutely progressive cognitive decline is more likely to be a comorbid condition like Alzheimer disease and, thus, deserves appropriate evaluation and treatment (see  <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Evaluation'</a>). Patients with HIV have not been shown to have a higher incidence of Alzheimer disease, and the cerebrospinal fluid (CSF) and imaging findings characteristic of Alzheimer disease are not found in HAD patients [<a href="#rid53">53-55</a>].</p><p>Other general comorbidities that have been associated with HAND include anemia, vascular disease, and metabolic abnormalities (including increased waist circumference and insulin resistance), particularly in older adults [<a href="#rid56">56-62</a>]. Traditional cardiovascular risk factors are associated with a higher risk for dementia in the general population and in patients with HIV and are more strongly associated with neurocognitive impairments than are HIV risk factors, such as CD4 cell count or viral load [<a href="#rid63">63</a>]. </p><p>Coinfection with hepatitis C virus (HCV) has also been identified as a possible, but not universally identified [<a href="#rid64">64</a>], risk factor for greater neurocognitive deficits in the setting of HIV infection [<a href="#rid65">65-67</a>]. It has been hypothesized that HCV could have direct neurotoxic effects. As an example, HCV RNA as well as nonstructural and core proteins have been detected in CSF and brain tissue; HCV may traffic into the CNS via macrophages and infect microglia and astrocytes, and HCV core protein may cause neuronal damage through the production of proinflammatory cytokines [<a href="#rid68">68-73</a>]. </p><p>Prior infection with <em>Toxoplasma</em> has also been associated with neurocognitive deficits [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H261704804"><span class="h3">Host genetic factors</span><span class="headingEndMark"> — </span>Whether there are associations between specific genetic factors and HAND is uncertain, and data are mixed. Polymorphisms in several genes, including those encoding apolipoprotein E4, the chemokine receptor CCR2, and monocyte chemoattractant protein-1, have been associated with the presence or development of HAD [<a href="#rid75">75-77</a>]. However, a genome-wide association study that involved 1287 patients from the Multicenter AIDS Cohort Study did not detect an association between those or any other polymorphisms and HAND or HAD [<a href="#rid78">78</a>]. Other studies evaluating apolipoprotein E4 genotype specifically have also not found an association with HAND [<a href="#rid79">79,80</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H77004370"><span class="h2">Spectrum of findings by ART status</span><span class="headingEndMark"> — </span>Antiretroviral treatment (ART) status impacts the presentation of HIV-associated neurocognitive disorders (HAND). The most severe form, HIV-associated dementia (HAD), typically occurs in patients with advanced, untreated HIV infection, with CD4 cell counts &lt;200 cells/microL and high plasma viral levels. This is much less likely to occur in patients on ART, among whom it is more common to find milder deficits that are residual or develop more indolently. Rarely, successfully treated patients can present with a "CNS escape syndrome," in which deficits as severe and subacutely progressive as those seen in HAD develop with detectable HIV in the CSF despite plasma viral suppression on antiretroviral therapy (ART). </p><p>The following sections discuss the clinical findings of these syndromes in more detail.</p><p class="headingAnchor" id="H2423796874"><span class="h2">HIV-associated dementia</span><span class="headingEndMark"> — </span>HIV-associated dementia (HAD), in its classic form, is primarily characterized by subcortical dysfunction, with attention-concentration impairment, depressive symptoms, and impaired psychomotor speed and precision; this is consistent with pathology suggesting that HIV affects predominantly subcortical and deep grey matter structures [<a href="#rid81">81,82</a>]. It occurs predominantly in untreated patients with advanced HIV infection. The onset of the impairments is typically subacute. Some emphasize that the deficits associated with HAD may wax and wane over time [<a href="#rid83">83</a>], unlike the progressive neurological decline seen in other neurodegenerative diseases, such as Alzheimer disease. </p><p class="headingAnchor" id="H9"><span class="h3">Cognitive deficits</span><span class="headingEndMark"> — </span>Prominent features of HAD include substantial memory deficits, impaired executive functioning, poor attention and concentration, mental slowing, and apathy [<a href="#rid84">84,85</a>]. Typically, cognitive deficits are evident and clearly impair functional status. Patients with HAD are often too slow and forgetful to work or prepare meals and can get lost while walking or driving [<a href="#rid86">86</a>]. Judgement, however, frequently remains relatively intact.</p><p>The absence of higher cortical dysfunction including aphasia, agnosia, and apraxia help distinguish HAD from classical "cortical" dementia, such as Alzheimer disease. However, the distinction between cortical and subcortical dementias can be blurred as a patient with late and severe HAD may have dysfunction in both language and praxis.</p><p class="headingAnchor" id="H3934148"><span class="h3">Behavioral and mood changes</span><span class="headingEndMark"> — </span>Behavioral changes in HAD are commonly characterized by apathy and lack of motivation (abulia) [<a href="#rid86">86</a>]. Patients with HAD may also display irritable mood, sleeplessness, weight loss, restlessness, and anxiety. Although these changes may be attributed to depression, patients with HAD are not typically dysphoric, and lack crying spells or reported sadness.</p><p>However, mood-changes associated with HAD may progress to psychosis with paranoid ideas and hallucinations. Furthermore, a small proportion of patients with HAD may develop mania. (See  <a class="medical medical_review" href="/z/d/html/4864.html" rel="external">"Depression, mania, and schizophrenia in patients with HIV"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Motor symptoms and signs</span><span class="headingEndMark"> — </span>Most patients with frank HAD exhibit slowness of movement (tested by rapid finger opposition or toe tapping) and gait (assessed by a timed gait test). In addition, patients can experience impaired saccadic eye movements, marked difficulty with smooth limb movement (especially in the lower extremities), dysdiadochokinesia, hyperreflexia, and frontal release signs such as grasp, root, snout, and glabellar reflexes.</p><p class="headingAnchor" id="H261704377"><span class="h3">Imaging findings</span><span class="headingEndMark"> — </span>In patients with HAD, cerebral atrophy is typically evident on brain imaging [<a href="#rid87">87,88</a>]. It affects mainly the basal ganglia (particularly the caudate) and white matter, but also cortical regions. On magnetic resonance imaging (MRI), T2-weighted images also demonstrate diffuse or patchy white matter hyperintensity  (<a class="graphic graphic_diagnosticimage graphicRef82180" href="/z/d/graphic/82180.html" rel="external">image 1</a>), which may correlate neuropathologically with high levels of HIV in those regions of the brain [<a href="#rid89">89</a>]. Some of these findings are common in older patients with and without cognitive impairment. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Findings'</a>.) </p><p>More advanced neuroimaging techniques, such as magnetic resonance spectroscopy, functional MRI, and positron emission tomography (PET), also demonstrate abnormalities in the subcortical regions, in some cases even in patients with more mild neurocognitive deficits [<a href="#rid53">53,87,90-93</a>]. </p><p class="headingAnchor" id="H2423797173"><span class="h3">CSF findings</span><span class="headingEndMark"> — </span>In observational studies, patients with HAD who are not on ART often have elevated cerebrospinal fluid (CSF) protein and elevated HIV levels in the CSF. Lymphocytic pleocytosis in the CSF is variable. However, these findings are not specific to patients with HAD and are observed in many untreated patients with HIV without neurocognitive impairment. As an example, in a cross-sectional study that included 46 untreated patients with HIV, the mean CSF viral level in this population was 3.6 log copies/mL, and the CSF white blood cell count ranged from 0 to 11 cells/microL [<a href="#rid94">94</a>]. There was no association between the presence of neurologic deficits and the CSF HIV level. However, in our experience and some observational studies, a CSF viral load that is equal to or greater than the plasma viral load is associated with HAD [<a href="#rid95">95,96</a>]. </p><p>Additionally, in untreated patients with HAD, the drug resistance profile of the CSF virus may differ from that of the plasma virus, although there has been no direct evidence that such differences are clinically important [<a href="#rid97">97</a>]. </p><p>Of note, testing of HIV viral levels and genotype in the CSF is not widely available, is not diagnostically informative in most cases of HAD, and is not routinely performed. (See <a class="local">'Severe deficits, not on ART'</a> below.)</p><p class="headingAnchor" id="H2586879331"><span class="h2">Milder neurocognitive deficits</span><span class="headingEndMark"> — </span>In the full spectrum of HAND, the cognitive deficits reported are more diverse and variable than those initially reported in HAD [<a href="#rid98">98</a>]. Successfully treated patients typically present with milder cognitive impairments.</p><p>The main cognitive deficits reported in milder presentations of HAND include difficulty with attention and working memory, executive functioning (eg, complex problem solving), and speed of informational processing [<a href="#rid3">3,87</a>]. The majority of patients with HIV who have evidence of such neurocognitive defects on testing actually have no evident symptoms or impairment in functioning (ie, asymptomatic neurocognitive impairment [ANI]). For those with mild symptomatic disease (ie, mild neurocognitive disorder [MND]), these deficits may manifest as difficulty with reading, performing complex tasks, or maintaining concentration in conversations or activities. Such symptoms may be subtle and overlooked or attributed to fatigue or other illness. Early language deficits are uncommon [<a href="#rid99">99</a>].</p><p>The onset and time course of cognitive deficits in milder forms of HAND is generally more indolent than the typically subacute presentation of HAD, and deficits may remain stable or seemingly unchanged for years [<a href="#rid86">86</a>].</p><p>Motor problems are not common in milder cases of HAND. Early motor symptoms can include unsteady gait, slowed or clumsy fine hand coordination (eg, a change in handwriting), or tremor [<a href="#rid99">99</a>]. Individuals may notice difficulties in performing activities that depend on fine coordination or rapid movements. On exam, rapid movement and gait may be slowed. </p><p>Affective disturbance is frequently associated with HAND [<a href="#rid100">100</a>]. Early manifestations may include apathy, lethargy, loss of sexual drive, and diminished emotional responsiveness. </p><p>Patients with mild neurocognitive deficits typically have normal brain imaging; findings similar to those of HAD, with cerebral atrophy or white matter abnormalities, can rarely be seen. Thus, imaging findings cannot distinguish these patients. Likewise, routine CSF studies do not distinguish them from patients with HIV without neurocognitive impairment. (See <a class="local">'Imaging findings'</a> above and <a class="local">'CSF findings'</a> above.)</p><p class="headingAnchor" id="H2423796465"><span class="h2">CNS viral escape syndrome</span><span class="headingEndMark"> — </span>Several studies have described an uncommon condition in ART-treated patients who present with severe new-onset neurological deficits and exhibit "CNS viral escape," in which there is evidence of CNS HIV replication in the CSF despite low viral levels or viral suppression in the plasma [<a href="#rid101">101-104</a>]. In most, there is also documented drug resistance in the CSF virus. </p><p>As examples, two retrospective studies described 10 and 11 patients, respectively, who developed new neurocognitive symptoms without alternate diagnosis and had detectable CSF HIV RNA (range 558 to 12885 and 134 to 9056 copies/mL) despite stable ART and virologic control in the plasma (at least &lt;500 copies/mL, most had &lt;50 copies/mL) [<a href="#rid101">101,103</a>]. The clinical presentations were heterogeneous, with some having a HAD-like presentation and others with more focal neurological manifestations accompanied by multifocal MRI lesions. CSF pleocytosis was present in most. A predominance of CD8 pleocytosis has also been described in a few patients with potential CNS escape syndrome [<a href="#rid104">104</a>]. Viral drug resistance mutations were identified in the majority of cases in which genotyping of the CSF virus was performed, suggesting "compartmentalization" of resistant virus within the CSF. In this isolated clinical setting, evaluating the CSF for HIV RNA level and genotype can be valuable to diagnose CNS viral escape and guide antiretroviral regimen changes. (See <a class="local">'Severe deficits, on ART'</a> below.)</p><p>This syndrome of symptomatic CNS escape in a previously asymptomatic or minimally symptomatic patient, as described in these cases, is rare. It should be clearly distinguished from asymptomatic, minor elevations of CSF HIV RNA levels despite plasma viral suppression that have been reported in several studies [<a href="#rid105">105,106</a>]. As an example, in a study of 1264 patients with viral suppression on ART who were followed for a median of 30 months and underwent lumbar puncture testing, detectable CSF HIV RNA was observed in 55 patients (7.1 percent) [<a href="#rid106">106</a>]. However, there was no association with detectable CSF HIV RNA and neurocognitive performance. Previous smaller retrospective series, generally consisting of fewer than 100 patients with plasma virologic suppression, described detectable CNS HIV RNA &gt;50 copies/mL in 5 to 23 percent [<a href="#rid102">102,103,107</a>]. There were no clear associations with detectable CSF HIV and neurocognitive function in those studies either, although there was an association with mild elevations of CSF neopterin, a marker of macrophage activation.</p><p class="headingAnchor" id="H1492901729"><span class="h2">Immune reconstitution inflammatory syndrome</span><span class="headingEndMark"> — </span>Very rarely, new-onset severe neurological symptoms may represent immune reconstitution inflammatory syndrome (IRIS) related to HIV CNS infection itself. This can present with severe CD8 cell encephalitis, with diffuse white and gray matter abnormalities on MRI and CD8 cell pleocytosis in the CSF [<a href="#rid104">104,108</a>].</p><p class="headingAnchor" id="H459496007"><span class="h1">SCREENING FOR DEFICITS</span><span class="headingEndMark"> — </span>For patients who do not report or have evident neurocognitive deficits, screening may be able to identify mild deficits. However, the value of broadly screening patients with HIV for neurocognitive impairment is controversial. Arguments in its favor include the potential value of identifying deficits that might affect medication adherence. However, the speculation that patients identified by neurocognitive impairment screening might benefit from use of antiretroviral regimens that optimally penetrate the central nervous system has not been supported by clinical trial evidence [<a href="#rid109">109</a>]. Other arguments against the practice include its consumption of precious resources in the busy clinical setting. Given limited resources and the absence of clear evidence to support changing management on the basis of mild deficits, we do not routinely screen for such deficits. However, when resources allow, screening is reasonable to establish a baseline assessment of a patient’s neurocognitive function in case there is subsequent deterioration.</p><p>Screening for deficits can be done by inquiring about symptoms and/or performing brief neurocognitive tests in the clinic. Some experts have suggested the following series of questions [<a href="#rid32">32,110</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Do you experience frequent memory loss (eg, do you forget the occurrence of special events, even the more recent ones, appointments, etc.)? </p><p class="bulletIndent1"><span class="glyph">●</span>Do you feel that you are slower when reasoning, planning activities, or solving problems?</p><p class="bulletIndent1"><span class="glyph">●</span>Do you have difficulties paying attention (eg, to a conversation, a book, or a movie)?</p><p></p><p>For each question, patients can answer "never," "hardly ever," or "yes, definitely." A "yes, definitely" answer to any of the three questions can prompt further evaluation. While a symptom-based approach would overlook the subset of patients with asymptomatic neurocognitive impairment (ANI), it may be the easiest for clinicians to implement.</p><p>Additional screening tools for neurocognitive function have been evaluated in patients with HIV. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmocacognition.com%2F&amp;token=b1YIhadNeg05BKW8lyJLG6R8uyFrFmc0HH66MOxJEZUbNyex33RJEu89nNTONJ3l&amp;TOPIC_ID=3723" target="_blank">Montreal Cognitive Assessment</a> (MoCA) can be performed in the office in less than 10 minutes and may be the most practical bedside test for periodic assessment [<a href="#rid111">111-115</a>]. The CogState-based assessment has reasonably good performance but is not publicly available [<a href="#rid116">116-119</a>]. The HIV Dementia Scale and the International Dementia Scale may not be highly sensitive for mild cognitive impairments [<a href="#rid120">120-122</a>]. Additionally, the mini-mental status examination does not thoroughly test executive function and is an insensitive tool for detection of HAND [<a href="#rid120">120,123</a>].</p><p>Some experts have recommended a screening interval of 6 to 24 months, depending on the presence of risk factors for HAND (see <a class="local">'Risk factors'</a> above) [<a href="#rid124">124,125</a>]. As an alternative, an approach that involves regularly screening every patient presenting for HIV care (such as having them complete a self-report screen in the waiting room), if feasible, allows the clinician to focus on determining next steps for those who screen positive instead of trying to decide whom and how often to screen.</p><p class="headingAnchor" id="H2610317289"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The possibility of an HIV-associated neurocognitive disorder (HAND) is suspected in patients with HIV who present with symptomatic cognitive deficits or are found to have deficits on screening tests. The diagnosis requires evaluation for pre-existing or alternative disorders that could account for the observed cognitive impairment, including other neurologic or neurodegenerative disorders, primary psychiatric disorders (eg, major depression, schizophrenia), severe substance use disorders, and complications of polypharmacy. Depending on the presentation, excluding alternate conditions may involve a number of laboratory tests and potentially neuroimaging (MRI) followed by cerebrospinal fluid (CSF) analysis.</p><p>Because of the frequency with which comorbid conditions exist in those with HAND, the assessment for persistent cognitive deficits should be made when pre-existing conditions are under optimal control. The differential diagnosis of cognitive impairment in patients with HIV is discussed in further detail below. (See <a class="local">'Differential diagnosis'</a> below.) </p><p class="headingAnchor" id="H77004391"><span class="h2">Initial assessment</span><span class="headingEndMark"> — </span>The goal of the initial assessment is to characterize the degree, time course, and functional impact of any cognitive deficits, establish the stage of HIV disease and treatment status, and start to evaluate for other potential causes of cognitive symptoms. </p><p class="headingAnchor" id="H2610317132"><span class="h3">Characterization of the cognitive impairment</span><span class="headingEndMark"> — </span>Characterizing cognitive deficits begins with a history from the patient and, if possible, family members or someone who knows the patient well. History should assess the domains affected by the cognitive impairment (eg, learning and memory, language, executive function), any accompanying behavioral or personality changes, the time course of symptoms, and particularly, the degree that any of these difficulties lead to functional impairment in common activities and in work. (See <a class="local">'Cognitive deficits'</a> above and <a class="local">'Milder neurocognitive deficits'</a> above.) </p><p>For patients who present with subacute or progressive symptoms typical of HIV-associated dementia (HAD), cognitive impairment that leads to functional deterioration is usually evident on such history and confirmed on bedside cognitive testing (see  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Cognitive testing'</a>). In such cases, formal neuropsychological testing is superfluous. </p><p>When the history is less clear and suggests a more static impairment or if impairments are only detected on screening tests, formal neuropsychological testing can be useful for establishing both the magnitude and profile of impairment. If performed, neuropsychological testing usually evaluates at least five of the following cognitive abilities [<a href="#rid3">3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Verbal/language</p><p class="bulletIndent1"><span class="glyph">●</span>Attention/working memory</p><p class="bulletIndent1"><span class="glyph">●</span>Abstraction/executive functioning</p><p class="bulletIndent1"><span class="glyph">●</span>Learning/recall </p><p class="bulletIndent1"><span class="glyph">●</span>Speed of informational processing</p><p></p><p class="headingAnchor" id="H2610317370"><span class="h3">Additional history and physical exam</span><span class="headingEndMark"> — </span>In addition to elucidating the extent and impact of cognitive impairment, history should evaluate for other potential causes of neurological impairment, including prior neurologic insults (eg, traumatic brain injury, vascular insults, other CNS infections) and major depressive, anxiety, and substance use disorders. A prevalent but often unappreciated issue is polypharmacy, which can result in cognitive impairment  (<a class="graphic graphic_table graphicRef70449" href="/z/d/graphic/70449.html" rel="external">table 1</a>); often, simplification of prescribed therapies, particularly sedating agents, antidepressants, and anticholinergic drugs, is helpful for cognition [<a href="#rid126">126,127</a>]. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'History'</a>.)</p><p>Both a general physical exam to evaluate for signs of alternate causes of cognitive impairment (eg, physical findings suggestive of thyroid or liver disease) and a dedicated neurologic exam should be performed. Findings of psychomotor slowness and hyperreflexia are suggestive of HAD. Other neurological findings could be suggestive of other causes of cognitive decline, such as rigidity and tremors in Parkinson's disease and a focal deficit in stroke or other focal brain lesions. Patients with HAND are characteristically alert; altered consciousness would be suggestive of alternative conditions. (See <a class="local">'Cognitive deficits'</a> above and <a class="local">'Behavioral and mood changes'</a> above and <a class="local">'Motor symptoms and signs'</a> above.)</p><p class="headingAnchor" id="H2610317404"><span class="h3">Laboratory testing</span><span class="headingEndMark"> — </span>Assessment of the stage of HIV infection (ie, with CD4 cell count and plasma viral load) is an important element in the evaluation of HAND. The CD4 cell count informs the likelihood that progressive cognitive impairment is due to HAD, which occurs predominantly (though not exclusively) at counts &lt;200 cells/microL in untreated patients. It also informs the differential diagnosis, as opportunistic infections that could cause cognitive impairment are more likely at lower CD4 cell counts. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Other laboratory testing that should be performed to evaluate for other causes of cognitive declines include a complete metabolic panel that includes liver function tests and glucose, vitamin B12 level, folate level, thyroid stimulating hormone, and serologic testing for syphilis and hepatitis C virus. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H77004416"><span class="h2">Further evaluation</span><span class="headingEndMark"> — </span>The focus of further diagnostic evaluation depends on the severity of the presentation and whether the patient is on ART, as outlined below.</p><p class="headingAnchor" id="H77004423"><span class="h3">Severe deficits, not on ART</span><span class="headingEndMark"> — </span>HAD develops almost exclusively in untreated patients with HIV, particularly when the CD4 cell count is &lt;200 cells/microL. Thus, additional diagnostic evaluation usually focuses on ruling out other opportunistic processes that such patients are at risk for and that can present with neurocognitive decline. </p><p>Neuroimaging with magnetic resonance imaging (MRI) is typically performed first to evaluate for other neurological disorders (infection, neoplasm, infarction, leukoencephalopathy) that can occur in untreated patients with HIV. Although these disorders are often suspected on the basis of history or exam, these disorders may sometimes present with predominantly cognitive impairment and no other localizing findings (see  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>). Diffuse cerebral atrophy and subcortical or periventricular white-matter changes (hypodense on computed tomography and bright on T2-weighted MRI) are consistent with HAD, but are neither sensitive nor specific. (See <a class="local">'Imaging findings'</a> above.)</p><p>Similarly, performance of other tests, including lumbar puncture for CSF evaluation, is done mainly to assess for other possible diagnoses. Such testing is guided by the clinical presentation and imaging findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with focal clinical or imaging features, toxoplasma blood serology (to assess susceptibility), CSF JC virus PCR (for diagnosis of progressive multifocal leukoencephalopathy), CSF EBV PCR (for primary CNS lymphoma), and CSF CMV PCR may be useful. (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions", section on 'Lumbar puncture'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a nonfocal presentation, CSF syphilis tests, CSF cryptococcal antigen, and CSF CMV PCR are usually assessed. </p><p></p><p>CSF findings in HAD can include elevated CSF protein and elevated ratio of CSF to blood albumin, but these routine assessments do not distinguish these patients from those without HAD. CSF HIV RNA levels in HAD also do not distinguish HAD patients; however, a CSF HIV RNA level that is equal to or greater than the plasma level is suggestive of HAD. (See <a class="local">'CSF findings'</a> above.)</p><p class="headingAnchor" id="H77004430"><span class="h3">Severe deficits, on ART</span><span class="headingEndMark"> — </span>In patients who are on ART, particularly if viremia is suppressed and the CD4 cell count has rebounded, neurological signs and symptoms are more likely due to non-HIV-related processes, such as cerebrovascular or neurodegenerative disease. Thus, the evaluation of such patients focuses on other non-HIV-related causes of neurocognitive decline, as would be done for uninfected individuals with cognitive decline. MRI and lumbar puncture are typically included in the evaluation. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/98647.html" rel="external">"Early-onset dementia in adults", section on 'Initial evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/98647.html" rel="external">"Early-onset dementia in adults", section on 'Additional testing'</a>.). </p><p>If no other causes are identified, there is the rare possibility that CNS escape syndrome underlies the cognitive decline. If this is suspected, CSF HIV RNA should also be evaluated, as CNS escape is characterized by detectable CSF HIV RNA despite plasma viral suppression. CSF pleocytosis in this setting may also be suggestive of CSF escape, since a normal CSF cell count is typically seen in patients on ART. Additionally, genotypic testing of the CSF virus can potentially help guide management in this limited setting. CSF HIV viral load testing is not readily available to all clinicians since it is not a generally approved laboratory test. If the clinical laboratory will not perform HIV viral load or genotypic testing on CSF, CSF can be frozen and sent to a research or commercial laboratory that does perform those assays. (See  <a class="medical medical_review" href="/z/d/html/98405.html" rel="external">"HIV-associated neurocognitive disorders: Management", section on 'Evaluating CSF for HIV'</a>.)</p><p>Even more rarely, new-onset severe neurological symptoms in patients on ART can represent immune reconstitution inflammatory syndrome. This is suggested by diffuse white and gray matter abnormalities on MRI and, if performed, CD8 cell pleocytosis in the CSF. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> above.) </p><p class="headingAnchor" id="H77004453"><span class="h3">Mild deficits</span><span class="headingEndMark"> — </span>Whether additional neurological evaluation is warranted for patients with mild deficits depends on the severity of symptoms and signs, the presence of alternate explanations, and whether the impairment is of recent onset or longstanding. In general, for patients with very mild symptoms, without functional impairment in work or daily life, and without recent onset or progression, it is reasonable to follow symptoms and signs without further dedicated neurological evaluation. In those with more prominent symptoms, functional impairment, or recent onset of deficits, additional evaluation is similar to that for patients with more severe deficits, with MRI and, in some instances, lumbar puncture for CSF evaluation. (See <a class="local">'Severe deficits, not on ART'</a> above and <a class="local">'Severe deficits, on ART'</a> above.)</p><p class="headingAnchor" id="H2610317599"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of an HIV-associated neurocognitive disorder (HAND) is made in a patient with HIV who has neurocognitive impairment (particularly if it is new onset or there is suggestion of progression) by history and exam or by detection of cognitive impairment through neuropsychological testing, and whose deficits cannot be fully explained by alternate conditions or pre-existing causes after thorough evaluation. (See <a class="local">'Evaluation'</a> above.) </p><p>Strictly speaking, classification of deficits as HIV-associated dementia (HAD), minor neurocognitive disorder (MND), or asymptomatic neurocognitive impairment (ANI) requires formal neuropsychological testing. However, comprehensive neuropsychological testing is costly, requires highly skilled professionals for administration and interpretation, and may not be readily accessible. From a practical standpoint, HAD can often be diagnosed in the absence of formal neuropsychological testing on the basis of more severe cognitive and motor dysfunction that substantially impairs functioning, and MND on the basis of symptoms or signs of milder cognitive decline that impair functioning. ANI, by definition, can only be diagnosed by formal testing. (See <a class="local">'Terminology'</a> above.)</p><p>The rare CNS viral escape syndrome can be diagnosed in patients who have virologic suppression on antiretroviral therapy (ART) and yet develop subacute progressive cognitive deficits that are unexplained by other conditions and accompanied by detectable CSF HIV RNA levels.</p><p class="headingAnchor" id="H12"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Cognitive impairment in patients with HIV may be a presenting symptom of numerous other disease processes. The differential diagnosis depends on the degree of immunosuppression and whether the patient is off or on antiretroviral agents. Among these are the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) infections – In patients with CD4 cell counts &lt;200 cells/microL, other CNS infections that can cause cognitive deficits are toxoplasmosis and progressive multifocal leukoencephalopathy (PML, caused by JC virus infection), both of which usually present with focal deficits and can be detected by magnetic resonance imaging (MRI). Cryptococcal meningitis is also relatively common in this setting, is usually nonfocal with headache and altered mentation, and is diagnosed by cryptococcal antigen or growth in the CSF. CMV encephalitis also can occur in these patients and may be nonfocal or occasionally include focal features; it is diagnosed by CSF CMV PCR testing. In patients with any CD4 cell count, neurosyphilis is an important consideration and can be differentiated by CSF testing for syphilis. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Who should be evaluated for neurosyphilis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CNS malignancies (eg, primary CNS lymphoma) – Primary CNS lymphoma associated with EBV infection presents much like toxoplasmosis and PML with focal manifestation and a mass lesion on imaging, although depending on the location of the mass, it may present only with changes in cognition and behavior. Imaging findings usually distinguish it from HIV-associated dementia (HAD). (See  <a class="medical medical_review" href="/z/d/html/4751.html" rel="external">"HIV-related lymphomas: Primary central nervous system lymphoma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other dementia syndromes – With longer survival, patients with well-controlled HIV infection on antiretroviral treatment may develop other dementing illnesses. Alzheimer disease is usually distinguished by early and relatively isolated memory loss followed by other "cortical" abnormalities, such as aphasia and apraxia. CSF biomarkers of Alzheimer disease (t- and p-tau and amyloid beta 1-42) or amyloid positron emission tomographic (PET) scanning can be used to establish the Alzheimer diagnosis. Early recognition of these biomarkers can enhance the diagnosis and should be checked in patients with HIV and severe cognitive decline [<a href="#rid128">128</a>]. Given emerging options for treatment of Alzheimer disease, consideration of this diagnosis is of increasing importance [<a href="#rid129">129,130</a>]. Vascular dementia can present much like HAD with subcortical features but is usually distinguished by a background of hypertension, episodes of lacunar stroke, and distinct MRI findings. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Dementia syndromes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional deficiencies (eg, vitamin B12 deficiency) – Cognitive impairment secondary to vitamin B12 deficiency can be accompanied by other neurologic symptoms, including paresthesias and sensory deficits. Vitamin B12 deficiency is not uncommon in the setting of HIV infection and can be easily identified through laboratory testing. (See  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine disorders (eg, thyroid dysfunction and adrenal insufficiency) – Hormonal aberrations are also frequent findings in HIV infection and can lead to confusion and other cognitive deficits. These can also be easily identified through laboratory testing. While gonadal insufficiency is a common finding in the aging HIV population, the impact of that on cognition is not well established. (See  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13969.html" rel="external">"Hypogonadism in males with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe substance use or psychiatric disorder – These are frequent comorbidities and confounders in the diagnosis of HAND and are often evident on detailed history. (See  <a class="medical medical_review" href="/z/d/html/3725.html" rel="external">"Substance use disorder in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/4864.html" rel="external">"Depression, mania, and schizophrenia in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delirium – Patients with delirium have a reduced ability to sustain, focus, or shift attention, which occurs over a short period of time. The presence of a disturbance in consciousness is a key factor in distinguishing delirium from HAND, in which the patient has a clear level of consciousness. (See  <a class="medical medical_review" href="/z/d/html/4860.html" rel="external">"Overview of the neuropsychiatric aspects of HIV infection and AIDS", section on 'Delirium'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polypharmacy – Various drugs, in particular anticholinergic agents, opioids, and anxiolytics, can negatively impact cognition  (<a class="graphic graphic_table graphicRef70449" href="/z/d/graphic/70449.html" rel="external">table 1</a>) [<a href="#rid126">126,127</a>]. Discontinuing some of these medications can potentially improve associated cognitive impairment.</p><p></p><p class="headingAnchor" id="H2590175121"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111628.html" rel="external">"Society guideline links: Primary care of adults with HIV"</a>.)</p><p class="headingAnchor" id="H23472521"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83082.html" rel="external">"Patient education: HIV-associated neurocognitive disorders (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H44685661"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology </strong>–<strong> </strong>Changes in memory, concentration, attention, and motor skills are common in patients with HIV. When these occur without an evident cause other than HIV infection, such impairments have been collectively classified as HIV-associated neurocognitive disorders (HAND). Depending on the severity and impact on daily functioning, cognitive deficits can be classified into three conditions: asymptomatic neurocognitive impairment (ANI), HIV-associated mild neurocognitive disorder (MND), and HIV-associated dementia (HAD). (See <a class="local">'Introduction'</a> above and <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>The widespread use of combination antiretroviral therapy (ART) has been associated with a decrease in the prevalence of more severe neurocognitive deficits (ie, HAD), but milder cognitive deficits without alternative explanation remain common in the setting of HIV infection, even among patients with viral suppression. Risk factors for HAND include low nadir CD4 cell count, age, and other comorbidities, such as cardiovascular and metabolic disease. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HIV-associated dementia </strong>–<strong> </strong>HAD occurs predominantly in untreated patients with advanced HIV infection. In its classic form, it is primarily characterized by subcortical dysfunction, with attention-concentration impairment, depressive symptoms, and impaired psychomotor speed and precision. The onset of the impairments is typically subacute. Cerebral atrophy is typically evident on brain imaging, which can also demonstrate diffuse or patchy white matter hyperintensity. (See <a class="local">'HIV-associated dementia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Milder neurocognitive deficits </strong>–<strong> </strong>The main cognitive deficits reported in milder presentations of HAND include difficulty with attention and working memory, executive functioning, and speed of informational processing. The onset and time course is generally more indolent than the typically subacute presentation of HAD, and deficits may remain stable or seemingly unchanged for years. There are no specific imaging findings. (See <a class="local">'Milder neurocognitive deficits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for deficits </strong>–<strong> </strong>The value of broadly screening patients with HIV for neurocognitive impairment is controversial. Given limited resources and the absence of clear evidence to support changing management on the basis of mild deficits, we do not routinely screen for such deficits. However, when resources allow, screening is reasonable to establish a baseline assessment of a patient’s neurocognitive function in case there is subsequent deterioration. (See <a class="local">'Screening for deficits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial assessment </strong>–<strong> </strong>The possibility of HAND is suspected in patients with HIV who present with symptomatic cognitive deficits or are found to have deficits on screening tests. The goal of the initial assessment is to characterize the degree, time course, and functional impact of any cognitive deficits, establish the stage of HIV disease and treatment status, and start to evaluate for other potential causes of cognitive symptoms, such as other neurologic or neurodegenerative disorders, primary psychiatric disorders, severe substance use disorders, and polypharmacy. (See <a class="local">'Initial assessment'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Further evaluation </strong>–<strong> </strong>The focus of further diagnostic evaluation depends on the severity of the presentation and whether the patient is on ART. For patients with very mild symptoms, without functional impairment in work or daily life, and without recent onset or progression, it is reasonable to follow symptoms and signs without further dedicated neurological evaluation. For patients with severe deficits, magnetic resonance imaging (MRI) and lumbar puncture for cerebrospinal fluid evaluation are generally performed to evaluated for other potential etiologies. (See <a class="local">'Further evaluation'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of HAND is made in a patient with HIV who has neurocognitive impairment (particularly if it is new onset or there is suggestion of progression) by history and exam or by detection of cognitive impairment through neuropsychological testing, and whose deficits cannot be fully explained by alternate conditions or pre-existing causes after thorough evaluation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3335627644"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard Price, MD, Alexander Thompson, MD, MBA, MPH, Andrew Pieper, MD, PhD, and Glenn Treisman, MD, PhD, who contributed to an earlier version of this topic review.</p><p>UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shapshak P, Kangueane P, Fujimura RK, et al. Editorial neuroAIDS review. AIDS 2011; 25:123.</a></li><li><a class="nounderline abstract_t">Price RW. Neurological complications of HIV infection. Lancet 1996; 348:445.</a></li><li><a class="nounderline abstract_t">Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789.</a></li><li><a class="nounderline abstract_t">Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011; 11:356.</a></li><li><a class="nounderline abstract_t">Nightingale S, Dreyer AJ, Saylor D, et al. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward. Clin Infect Dis 2021; 73:1113.</a></li><li><a class="nounderline abstract_t">McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007; 21:1109.</a></li><li><a class="nounderline abstract_t">Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012; 206:275.</a></li><li><a class="nounderline abstract_t">Price RW, Spudich SS, Peterson J, et al. Evolving character of chronic central nervous system HIV infection. Semin Neurol 2014; 34:7.</a></li><li><a class="nounderline abstract_t">Winston A, Spudich S. Cognitive disorders in people living with HIV. Lancet HIV 2020; 7:e504.</a></li><li><a class="nounderline abstract_t">Keng LD, Winston A, Sabin CA. The global burden of cognitive impairment in people with HIV. AIDS 2023; 37:61.</a></li><li><a class="nounderline abstract_t">Killingsworth L, Spudich S. Neuropathogenesis of HIV-1: insights from across the spectrum of acute through long-term treated infection. Semin Immunopathol 2022; 44:709.</a></li><li><a class="nounderline abstract_t">González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69.</a></li><li><a class="nounderline abstract_t">Wang T, Gong N, Liu J, et al. HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol 2008; 3:173.</a></li><li><a class="nounderline abstract_t">Li GH, Henderson L, Nath A. Astrocytes as an HIV Reservoir: Mechanism of HIV Infection. Curr HIV Res 2016; 14:373.</a></li><li><a class="nounderline abstract_t">Donoso M, D'Amico D, Valdebenito S, et al. Identification, Quantification, and Characterization of HIV-1 Reservoirs in the Human Brain. Cells 2022; 11.</a></li><li><a class="nounderline abstract_t">Moroni M, Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. AIDS 2003; 17 Suppl 1:S51.</a></li><li><a class="nounderline abstract_t">Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14:69.</a></li><li><a class="nounderline abstract_t">Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003; 13:195.</a></li><li><a class="nounderline abstract_t">Gray F, Chrétien F, Vallat-Decouvelaere AV, Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62:429.</a></li><li><a class="nounderline abstract_t">Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology 2012; 79:2328.</a></li><li><a class="nounderline abstract_t">Edén A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after &gt;4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196:1779.</a></li><li><a class="nounderline abstract_t">Burdo TH, Ellis RJ, Fox HS. Osteopontin is increased in HIV-associated dementia. J Infect Dis 2008; 198:715.</a></li><li><a class="nounderline abstract_t">Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.</a></li><li><a class="nounderline abstract_t">Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011; 57:371.</a></li><li><a class="nounderline abstract_t">Pulliam L, Rempel H, Sun B, et al. A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations. AIDS 2011; 25:1721.</a></li><li><a class="nounderline abstract_t">Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 2012; 60:234.</a></li><li><a class="nounderline abstract_t">Cochrane CR, Angelovich TA, Byrnes SJ, et al. Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART. Ann Neurol 2022; 92:532.</a></li><li><a class="nounderline abstract_t">d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55:320.</a></li><li><a class="nounderline abstract_t">Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63:213.</a></li><li><a class="nounderline abstract_t">Lescure FX, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 2011; 52:235.</a></li><li><a class="nounderline abstract_t">Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 2013; 80:371.</a></li><li><a class="nounderline abstract_t">Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243.</a></li><li><a class="nounderline abstract_t">Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915.</a></li><li><a class="nounderline abstract_t">Pumpradit W, Ananworanich J, Lolak S, et al. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol 2010; 16:76.</a></li><li><a class="nounderline abstract_t">Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087.</a></li><li><a class="nounderline abstract_t">Bonnet F, Amieva H, Marquant F, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS 2013; 27:391.</a></li><li><a class="nounderline abstract_t">Heaton RK, Franklin DR Jr, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 2015; 60:473.</a></li><li><a class="nounderline abstract_t">Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology 2016; 86:334.</a></li><li><a class="nounderline abstract_t">Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3.</a></li><li><a class="nounderline abstract_t">Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18 Suppl 1:S75.</a></li><li><a class="nounderline abstract_t">Heaton RK, Ellis RJ, Tang B, et al. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study. Brain 2023; 146:1121.</a></li><li><a class="nounderline abstract_t">Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol 2012; 18:388.</a></li><li><a class="nounderline abstract_t">Cysique LA, Letendre SL, Ake C, et al. Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS 2010; 24:983.</a></li><li><a class="nounderline abstract_t">Mateen FJ, Shinohara RT, Carone M, et al. Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011. Neurology 2012; 79:1873.</a></li><li><a class="nounderline abstract_t">McDonnell J, Haddow L, Daskalopoulou M, et al. Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr 2014; 67:120.</a></li><li><a class="nounderline abstract_t">Maki PM, Rubin LH, Valcour V, et al. Cognitive function in women with HIV: findings from the Women's Interagency HIV Study. Neurology 2015; 84:231.</a></li><li><a class="nounderline abstract_t">Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort. J Neurovirol 2006; 12:387.</a></li><li><a class="nounderline abstract_t">Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A 2006; 103:15160.</a></li><li><a class="nounderline abstract_t">Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18 Suppl 1:S27.</a></li><li><a class="nounderline abstract_t">Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63:822.</a></li><li><a class="nounderline abstract_t">Sacktor N, Skolasky R, Selnes OA, et al. Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. J Neurovirol 2007; 13:203.</a></li><li><a class="nounderline abstract_t">Cysique LA, Maruff P, Bain MP, et al. HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 2011; 23:83.</a></li><li><a class="nounderline abstract_t">Ances BM, Christensen JJ, Teshome M, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: A case-control study. Neurology 2010; 75:111.</a></li><li><a class="nounderline abstract_t">Gisslén M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009; 9:63.</a></li><li><a class="nounderline abstract_t">Ortega M, Ances BM. Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol 2014; 9:483.</a></li><li><a class="nounderline abstract_t">McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012; 78:485.</a></li><li><a class="nounderline abstract_t">Valcour VG, Sacktor NC, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV cohort. J Acquir Immune Defic Syndr 2006; 43:405.</a></li><li><a class="nounderline abstract_t">McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43:2245.</a></li><li><a class="nounderline abstract_t">Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73:1292.</a></li><li><a class="nounderline abstract_t">Kalayjian RC, Wu K, Evans S, et al. Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals. J Acquir Immune Defic Syndr 2014; 67:30.</a></li><li><a class="nounderline abstract_t">Dufouil C, Richert L, Thiébaut R, et al. Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology 2015; 85:1065.</a></li><li><a class="nounderline abstract_t">Marquine MJ, Montoya JL, Umlauf A, et al. The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study. Clin Infect Dis 2016; 63:694.</a></li><li><a class="nounderline abstract_t">Moulignier A, Costagliola D. Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders. Curr Top Behav Neurosci 2021; 50:367.</a></li><li><a class="nounderline abstract_t">Clifford DB, Vaida F, Kao YT, et al. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology 2015; 84:241.</a></li><li><a class="nounderline abstract_t">Parsons TD, Tucker KA, Hall CD, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006; 20:1591.</a></li><li><a class="nounderline abstract_t">Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 2005; 11:265.</a></li><li><a class="nounderline abstract_t">Sun B, Abadjian L, Rempel H, et al. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr 2013; 62:190.</a></li><li><a class="nounderline abstract_t">Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 2002; 76:10064.</a></li><li><a class="nounderline abstract_t">Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76:600.</a></li><li><a class="nounderline abstract_t">Fishman SL, Murray JM, Eng FJ, et al. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 2008; 197:597.</a></li><li><a class="nounderline abstract_t">Laskus T, Radkowski M, Adair DM, et al. Emerging evidence of hepatitis C virus neuroinvasion. AIDS 2005; 19 Suppl 3:S140.</a></li><li><a class="nounderline abstract_t">Vivithanaporn P, Maingat F, Lin LT, et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One 2010; 5:e12856.</a></li><li><a class="nounderline abstract_t">Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196:361.</a></li><li><a class="nounderline abstract_t">Bharti AR, McCutchan A, Deutsch R, et al. Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults. Clin Infect Dis 2016; 63:1655.</a></li><li><a class="nounderline abstract_t">Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 2002; 99:13795.</a></li><li><a class="nounderline abstract_t">Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol 2004; 157:197.</a></li><li><a class="nounderline abstract_t">Singh KK, Ellis RJ, Marquie-Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol 2004; 157:185.</a></li><li><a class="nounderline abstract_t">Levine AJ, Service S, Miller EN, et al. Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. Am J Med Genet B Neuropsychiatr Genet 2012; 159B:669.</a></li><li><a class="nounderline abstract_t">Morgan EE, Woods SP, Letendre SL, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 2013; 19:150.</a></li><li><a class="nounderline abstract_t">Geffin R, McCarthy M. Aging and Apolipoprotein E in HIV Infection. J Neurovirol 2018; 24:529.</a></li><li><a class="nounderline abstract_t">Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19:517.</a></li><li><a class="nounderline abstract_t">Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19:525.</a></li><li><a class="nounderline abstract_t">Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63:2084.</a></li><li><a class="nounderline abstract_t">Berger JR, Brew B. An international screening tool for HIV dementia. AIDS 2005; 19:2165.</a></li><li><a class="nounderline abstract_t">Gallego L, Barreiro P, López-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev 2011; 13:171.</a></li><li><a class="nounderline abstract_t">Grill MF, Price RW. Central nervous system HIV-1 infection. Handb Clin Neurol 2014; 123:487.</a></li><li><a class="nounderline abstract_t">Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011; 25:561.</a></li><li><a class="nounderline abstract_t">Dal Pan GJ, McArthur JH, Aylward E, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology 1992; 42:2125.</a></li><li><a class="nounderline abstract_t">Archibald SL, Masliah E, Fennema-Notestine C, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol 2004; 61:369.</a></li><li><a class="nounderline abstract_t">Roc AC, Ances BM, Chawla S, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol 2007; 64:1249.</a></li><li><a class="nounderline abstract_t">Castelo JM, Courtney MG, Melrose RJ, Stern CE. Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise. Arch Neurol 2007; 64:1275.</a></li><li><a class="nounderline abstract_t">Saloner R, Heaton RK, Campbell LM, et al. Effects of comorbidity burden and age on brain integrity in HIV. AIDS 2019; 33:1175.</a></li><li><a class="nounderline abstract_t">Masters MC, Ances BM. Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol 2014; 34:89.</a></li><li><a class="nounderline abstract_t">Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.</a></li><li><a class="nounderline abstract_t">Bai F, Iannuzzi F, Merlini E, et al. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. AIDS 2017; 31:311.</a></li><li><a class="nounderline abstract_t">Ulfhammer G, Edén A, Antinori A, et al. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. Clin Infect Dis 2022; 75:493.</a></li><li><a class="nounderline abstract_t">Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41:1787.</a></li><li><a class="nounderline abstract_t">Tross S, Price RW, Navia B, et al. Neuropsychological characterization of the AIDS dementia complex: a preliminary report. AIDS 1988; 2:81.</a></li><li><a class="nounderline abstract_t">Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:778.</a></li><li><a class="nounderline abstract_t">Stern Y, McDermott MP, Albert S, et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 2001; 58:473.</a></li><li><a class="nounderline abstract_t">Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012; 26:1765.</a></li><li><a class="nounderline abstract_t">Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819.</a></li><li><a class="nounderline abstract_t">Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773.</a></li><li><a class="nounderline abstract_t">Lescure FX, Moulignier A, Savatovsky J, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis 2013; 57:101.</a></li><li><a class="nounderline abstract_t">Mukerji SS, Misra V, Lorenz DR, et al. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. Clin Infect Dis 2018; 67:1182.</a></li><li><a class="nounderline abstract_t">Pérez-Valero I, Ellis R, Heaton R, et al. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS 2019; 33:475.</a></li><li><a class="nounderline abstract_t">Rawson T, Muir D, Mackie NE, et al. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect 2012; 65:239.</a></li><li><a class="nounderline abstract_t">Costello DJ, Gonzalez RG, Frosch MP. Case records of the Massachusetts General Hospital. Case 18-2011. A 35-year-old HIV-positive woman with headache and altered mental status. N Engl J Med 2011; 364:2343.</a></li><li><a class="nounderline abstract_t">Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25:1747.</a></li><li class="breakAll">European AIDS Clinical Society Guidelines, October 2011. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf (Accessed on May 22, 2013).</li><li class="breakAll">Montral Cognitive Assessment. http://www.mocatest.org/ (Accessed on August 08, 2012).</li><li><a class="nounderline abstract_t">Milanini B, Wendelken LA, Esmaeili-Firidouni P, et al. The Montreal cognitive assessment to screen for cognitive impairment in HIV patients older than 60 years. J Acquir Immune Defic Syndr 2014; 67:67.</a></li><li><a class="nounderline abstract_t">Overton ET, Azad TD, Parker N, et al. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol 2013; 19:109.</a></li><li><a class="nounderline abstract_t">Brouillette MJ, Mayo N, Fellows LK, et al. A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? AIDS 2015; 29:895.</a></li><li><a class="nounderline abstract_t">Hakkers CS, Beunders AJM, Ensing MHM, et al. The Montreal Cognitive Assessment-Basic (MoCA-B) is not a reliable screening tool for cognitive decline in HIV patients receiving combination antiretroviral therapy in rural South Africa. Int J Infect Dis 2018; 67:36.</a></li><li><a class="nounderline abstract_t">Robertson K, Maruff P, Ross LL, et al. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir. J Neurovirol 2019; 25:22.</a></li><li><a class="nounderline abstract_t">Kamminga J, Bloch M, Vincent T, et al. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure. J Clin Exp Neuropsychol 2017; 39:753.</a></li><li><a class="nounderline abstract_t">Bloch M, Kamminga J, Jayewardene A, et al. A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis 2016; 63:687.</a></li><li><a class="nounderline abstract_t">Overton ET, Kauwe JS, Paul R, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav 2011; 15:1902.</a></li><li><a class="nounderline abstract_t">Valcour V, Paul R, Chiao S, et al. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 2011; 53:836.</a></li><li><a class="nounderline abstract_t">Bottiggi KA, Chang JJ, Schmitt FA, et al. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci 2007; 260:11.</a></li><li><a class="nounderline abstract_t">Sakamoto M, Marcotte TD, Umlauf A, et al. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr 2013; 62:36.</a></li><li><a class="nounderline abstract_t">Skinner S, Adewale AJ, DeBlock L, et al. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med 2009; 10:246.</a></li><li><a class="nounderline abstract_t">Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56:1004.</a></li><li class="breakAll">European AIDS Clinical Society Guidelines. Updated yearly. http://www.eacsociety.org/Guidelines.aspx.</li><li><a class="nounderline abstract_t">Rubin LH, Radtke KK, Eum S, et al. Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women. J Acquir Immune Defic Syndr 2018; 79:83.</a></li><li><a class="nounderline abstract_t">Cooley SA, Paul RH, Strain JF, et al. Effects of anticholinergic medication use on brain integrity in persons living with HIV and persons without HIV. AIDS 2021; 35:381.</a></li><li><a class="nounderline abstract_t">Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280.</a></li><li><a class="nounderline abstract_t">Li Y, Schindler SE, Bollinger JG, et al. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology 2022; 98:e688.</a></li><li><a class="nounderline abstract_t">van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med 2023; 388:9.</a></li></ol></div><div id="topicVersionRevision">Topic 3723 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076277" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Editorial neuroAIDS review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8709786" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neurological complications of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914061" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Updated research nosology for HIV-associated neurocognitive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22204557" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33904889" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502721" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551810" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Central nervous system viral invasion and inflammation during acute HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715483" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evolving character of chronic central nervous system HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32621876" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cognitive disorders in people living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36111550" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The global burden of cognitive impairment in people with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35882661" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neuropathogenesis of HIV-1: insights from across the spectrum of acute through long-term treated infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630430" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The neuropathogenesis of AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18587649" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : HIV-1-infected astrocytes and the microglial proteome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27719663" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Astrocytes as an HIV Reservoir: Mechanism of HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35954221" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Identification, Quantification, and Characterization of HIV-1 Reservoirs in the Human Brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870531" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10714569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Changes in pathological findings at autopsy in AIDS cases for the last 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12744473" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Changing patterns in the neuropathogenesis of HIV during the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12769183" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The changing pattern of HIV neuropathology in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23197750" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Structural brain alterations can be detected early in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18190258" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immune activation of the central nervous system is still present after&gt;4 years of effective highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616394" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Osteopontin is increased in HIV-associated dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575590" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646912" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750421" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569268" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35867351" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991809" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Changing incidence of central nervous system diseases in the EuroSIDA cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894380" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288850" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23303852" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996937" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721099" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The prevalence and incidence of neurocognitive impairment in the HAART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20053142" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135382" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079813" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cognitive disorders in HIV-infected patients: are they HIV-related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362201" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26718568" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21174240" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15075501" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477867" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22811264" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antiretroviral neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299964" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23077015" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neurologic disorders incidence in HIV+ vs HIV- men: Multicenter AIDS Cohort Study, 1996-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24991974" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540304" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cognitive function in women with HIV: findings from the Women's Interagency HIV Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065131" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015824" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15075495" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365130" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613710" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21304143" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : HIV and age do not substantially interact in HIV-associated neurocognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20534887" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028512" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24816714" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Role of HIV in amyloid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330412" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17099311" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232937" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841381" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25118793" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156515" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diabetes and cognitive decline in a French cohort of patients infected with HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27199461" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31989463" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25503616" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868439" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16036806" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23187938" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208987" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752151" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275278" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Molecular and bioinformatic evidence of hepatitis C virus evolution in brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251811" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Emerging evidence of hepatitis C virus neuroinvasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20877724" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597450" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27794019" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374865" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579298" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579296" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22628157" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408335" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987582" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Aging and Apolipoprotein E in HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3729308" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The AIDS dementia complex: I. Clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3014994" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The AIDS dementia complex: II. Neuropathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596754" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284467" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : An international screening tool for HIV dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799535" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015501" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Central nervous system HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160410" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : HIV-1 infection and cognitive impairment in the cART era: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1436522" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023814" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620480" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846265" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30870195" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of comorbidity burden and age on brain integrity in HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715492" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Role of neuroimaging in HIV-associated neurocognitive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16266436" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28005574" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34747481" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16288405" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132951" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Neuropsychological characterization of the AIDS dementia complex: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2046917" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255452" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Factors associated with incident human immunodeficiency virus-dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614889" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050119" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100092" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515205" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617912" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30702516" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22522289" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675893" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Case records of the Massachusetts General Hospital. Case 18-2011. A 35-year-old HIV-positive woman with headache and altered mental status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750419" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750419" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750419" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24872137" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The Montreal cognitive assessment to screen for cognitive impairment in HIV patients older than 60 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23345074" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25291105" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29183843" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The Montreal Cognitive Assessment-Basic (MoCA-B) is not a reliable screening tool for cognitive decline in HIV patients receiving combination antiretroviral therapy in rural South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30298202" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052738" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325690" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21877204" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21921226" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Screening for cognitive impairment in human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482212" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The HIV Dementia Scale: predictive power in mild dementia and HAART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111573" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187172" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175555" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175555" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781879" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33252494" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effects of anticholinergic medication use on brain integrity in persons living with HIV and persons without HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514248" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34906975" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Validation of Plasma Amyloid-β42/40 for Detecting Alzheimer Disease Amyloid Plaques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36449413" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lecanemab in Early Alzheimer's Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
